J&J's Janssen Gets CHMP Positive Opinion for Tremfya in Active Psoriatic Arthritis
October 16 2020 - 8:36AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on
Friday said the European Medicines Agency's Committee for Medicinal
Products for Human Use recommended expanded approval of Tremfya for
the treatment of adults with active psoriatic arthritis.
The drug maker said it expects a final decision from the
European Commission, which generally follows the CHMP's advice,
later this year.
Tremfya is currently approved in the EU for the treatment of
moderate to severe plaque psoriasis in adults who are candidates
for systemic therapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 16, 2020 08:21 ET (12:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
